Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Metabolife execs subpoenaed

This article was originally published in The Tan Sheet

Executive Summary

House Energy & Commerce Subcommittee on Oversight & Investigations authorizes issuance of three subpoenas to former and current Metabolife employees in 9-0 vote. During business meeting held July 10, Rep. Greg Walden (R-Ore.) noted that in response to hearing invitation letters sent to 13 individuals, three Metabolife witnesses "have sent written responses through their respective counsels declining the invitation to testify." Founder, co-owner and former president Michael Ellis, former president David Brown and current employee Daniel Rodriguez will be issued subpoenas "as quickly as possible," committee says. In response, Metabolife maintains it is cooperating with House investigation and "looks forward to having its senior officials, including" CEO Russell Schreck, testify. First of two hearings on ephedra is scheduled for July 23; House inquiry began in February (1"The Tan Sheet" March 3, 2003, p. 9)...

You may also be interested in...

Ephedra hearings

House Energy & Commerce Committee/Subcommittee on Oversight & Investigations plans second day of hearings on botanical July 24, following previously-announced July 23 session (1"The Tan Sheet" July 14, 2003, In Brief). Hearings will take place in room 2123 in the Rayburn office building...

Ephedra Safety Taken Up By House Commerce Cmte, Cytodyne Sent Letter

The House Energy & Commerce Committee launched an investigation into the safety of ephedra Feb. 28 by sending letters to FDA Commissioner Mark McClellan, MD/PhD, and Cytodyne Technologies President Robert Chinery

Future Use Of Titanium Dioxide In Spray And Powder Cosmetics Hinges On SCCS Review

As of 5 February, the Scientific Committee on Consumer Safety is evaluating use of titanium dioxide – now officially classified as a Category 2 carcinogen in the EU – in cosmetic products that can expose consumers by way of inhalation. Without a favorable SCCS opinion, the ingredient’s use in those contexts will be banned under Article 15 of the Cosmetics Regulation.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts